Common cancers - Genetics, origin, prevention, screening: Parts I and II

Disease-a-Month

Volumn 43, Issue 10, 1997, Pages 681-742

  Skeel, Roland T ^a,d,e,f,g   Schifeling, David J ^b,h,i,j,k,l   Horton, John ^c,m,n,o,p,q   Tafelski, Thomas J ^a,r,s,t  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e HENRY FORD HOSPITAL   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Medical College Hospital   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j INDIAN HEALTH SERVICE   (United States)

^k WAKE FOREST UNIVERSITY   (United States)

^l UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^m UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁿ ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^o ALBANY MEDICAL CENTER   (United States)

^p NATIONAL CANCER INSTITUTE   (United States)

^q UNIVERSITY OF SOUTH FLORIDA   (United States)

^r UNIVERSITY OF CINCINNATI   (United States)

^s OHIO UNIVERSITY   (United States)

^t American Board of Family Practice   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BREAST CARCINOMA; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DNA DAMAGE; GENE MUTATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; METASTASIS POTENTIAL; PROSTATE CANCER; REVIEW; SCREENING TEST; SKIN CANCER; UTERINE CERVIX CANCER;

EID: 84865937110     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-5029(97)90034-1     Document Type: Review

References (74)

1. Ford D, Easton DF, Bishop DT, et al. for the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
2. Struewing JP, Abeliovich D, Peretz T, er al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
3. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2 to chromosome 13q12-13. Science 1994;265:2088-90.
4. Strong LC, William WR, Tainsky MA. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 1992;135:190-9.
5. Boman BM, Levin B. Familial polyposis. Hosp Pract 1986;21:155-70.
6. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993;329:1982-7.
7. Lynch HT, Smyrck TC, Watson P, et al. Genetics, history, tumor spectrum, and pathology of hereditary non-polyposis colorectal cancer: an updated review. Gastroenterology 1993;104:1535-49.
8. Ionov YM, Peinado A, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-61.
9. Hodgson SV, Maher ER. A practical guide to human cancer genetics, New York: Cambridge University Press, 1993.
10. Offit K, Brown K. Quantitating familial cancer risk: a resource for clinical oncologists. J Clin Oncol 1994;12:1724-36.
11. Weber BL, Garber JE. Familial breast cancer. In: Harris JR, Lippman ME, Morrow S, et al., editors. Diseases of the breast. Philadelphia: Lippincott-Raven; 1996. p. 168-85.
12. Karnes PS. Ordering and interpreting DNA tests. Mayo Clin Proc 1996;71:1192-5.
13. Statement of the American Society of Clinical Oncology. Genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730-6.
14. Breo L. Altered fates: counseling families with inherited breast cancer. JAMA 1993;269:2017-22.
15. Hudson KL, Rothenberg KH, Andrews LB, et al. Genetic discrimination and health insurance: an urgent need for reform. Science 1995;270:391-3.
16. Kastan MB. Molecular biology of cancer: the cell cycle. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 121-34.
17. Green DR, Bissonnette RP, Cotter TG. Apoptosis and cancer. PPO Updates 1994;8:1-14.
18. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
19. Shields PG, Harris CC. Molecular epidemiology and the genetics of environmental cancer. JAMA 1991;226:681-7.
20. Weisburger JH, Williams GM. Causes of cancer. In: Murphy GP, Lawrence W, Lenhard RE, editors. American Cancer Society textbook of clinical oncology. 2nd ed. Atlanta: American Cancer Society; 1995. p. 10-39.
21. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1191-308.
22. Food guide pyramid: a guide to daily food choices. Home and Garden Bulletin 232. Washington (DC): Department of Agriculture; 1992.
23. The American Cancer Society 1996 Advisory Committee on Diet, Nutrition, and Cancer Prevention. Guidelines on diet, nutrition, and cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 1996;46:325-41.
24. National Cancer Institute. Diet, nutrition, and cancer prevention; the good news. Washington (DC): US Government Printing Office; 1986. Publication no. DHHS (NIH) 87-2878.
25. Counseling to promote a healthy diet. In: Report of the US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins; 1996. p. 625-42.
26. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
27. Fugh-Berman S. Should healthy women take tamoxifen? N Engl J Med 1992;327:1596-7.
28. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
29. Rosenberg I, Ralmer JR, Zauber AG, et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355-8.
30. Blum A. Cancer prevention: preventing tobacco-related cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 545-58.
31. Flore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994;271:1940-7.
32. Clark R. Principles of cancer screening. Cancer Control JMCC 1995;2:485-92.
33. Hulka BS. Cancer screening: degrees of proof and practical application. Cancer 1988;62:1776-80.
34. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237-43.
35. Peters J. Breast cancer genetics: relevance to oncology practice. Cancer Control JMCC 1995;2:195-208.
36. Rimer BK. Adherence to cancer screening. Cancer Control JMCC 1995;2:510-7.
37. Cancer Facts and Figures. Atlanta: American Cancer Society; 1997.
38. Lorincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-37.
39. Hoffman MS, Cavanagh D. Cervical cancer: screening and prevention of disease. Cancer Control JMCC 1995:2;503-9.
40. Andersen ES, Husth M. Cryosurgery for cervical intraepithelial neoplasia: 10-year follow up. Gynecol Oncol 1992;45:240-2.
41. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1947;53:609-17.
42. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott; 1993. p. 1264-332.
43. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
44. Clark R. Breast cancer screening: is it worthwhile? Cancer Control JMCC 1995;2:189-94.
45. Smart CR, Hendrick RE, Ruttledge JG, et al. Benefit of mammography screening in women ages 40-49. Cancer 1995;75:1619-26.
46. Levin B. Screening for colorectal cancer. Cancer Control JMCC 1996;3:20-5.
47. St. John DJ, Young GP, Alexeyeff MA, et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993;104:1661-8.
48. Mandel J. Screening for colon and rectal cancer. Cancer Control JMCC 1996;3:170-7.
49. Liberman D. Screening colonoscopy: has the time come? Gastrointest Endosc Clin North Am 1993;3:673-82.
50. Lynch HJ, Lynch JF. The Lynch syndrome: melding natural history and molecular genetics to genetic counseling and cancer control. Cancer Control JMCC 1996;3:13-9.
51. Wingo PA, Tony T, Bolden S. Cancer statistics, 1995. CA 1995;45:8-31.
52. Fiorica JV, Roberts WS. Screening for ovarian cancer. Cancer Control JMCC 1996;3:120-9.
53. Squadrito RC, Buller RE. Use of serum CA 125 for monitoring and prognosticating outcome in patients with epithelial ovarian cancer. Female Patient 1994;19:14.
54. Karlan BY, Platt LD. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. Gynecol Oncol 1994;55:529.
55. American College of Obstetricians and Gynecologists. Routine cancer screening. In: ACOG Technical Bulletin 128. Washington (DC): ACOG; 1993.
56. Mokulis J, Thompson I. Screening for prostate cancer: pros, cons, and reality. Cancer Control JMCC 1995;2:15-21.
57. Hostetler RM, Mandel IG, Marshburn J. Prostate cancer screening. Med Clin North Am 1996;80:83-98.
58. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate specific antigen in a community-based population of elderly men: establishment of age-specific reference ranges. JAMA 1993;270:860-4.
59. Cancer Facts and Figures 1996. Atlanta: American Cancer Society; 1996.
60. Wagner H, Ruckdeschel J. Screening, early detection and early intervention strategies for lung cancer. Cancer Control JMCC 1995;2:493-502.
61. Eng C. The ret proto-oncogene in multiple endocrine neoplasia type 2 and Hirchsprung's disease. N Engl J Med 1996;335:943-51.
62. Womeodu RJ, Bailey JE. Barriers to cancer screening. Med Clin North Am 1996;80:115-33.
63. Griffith RS, Williams PA. Barriers and incentives of physicians and patients to cancer screening. Primary Care 1992;18:535-56.
64. Caplan LS, Wells BL, Haynes S. Breast cancer screening among older racial/ethnic minorities and whites: barriers to early detection. J Gerontol 1992;47:101-10.
65. Schapira DV, Pamies RJ, Kumar NB, et al. Cancer screening: knowledge, recommendations, and practices of physicians. Cancer 1993;71:839-43.
66. Costanza ME, Hoople NE, Gaw VP, et al. Cancer prevention practices and continuing education needs of primary care. Am J Prev Med 1993;9:107-12.
67. Guide to Clinical Preventive Services. Report of the U.S. Preventive Services Task Force. 2nd ed. Alexandria (VA): International Medical Publishing; 1996.
68. Osborn EH, Bird JA, McPhee SJ. Cancer screening by primary care physicians. J Fam Pract 1991;32:465.
69. Frame P. The complete annual physical examination refuses to die. J Fam Pract 1995;40:543-5.
70. Sifri R, Wender RC. Preventive care: steps toward implementation. Primary Care 1996;23:127-40.
71. Cogswell B, Eggert M. People want doctors to give more preventive care: a qualitative study of healthcare consumers. Arch Fam Med 1993;2:611-9.
72. Dietrich A, Woodruff C, Carney P. Changing office routines to enhance preventive care: the preventive GAPS approach. Arch Fam Med 1994;3:176-83.
73. Frame P. Health maintenance in clinical practice: strategies and barriers. Am Fam Physician 1992;45:1192-200.
74. Frame P. Computerized health maintenance tracking systems: a clinician's guide to necessary and optional features. J Am Board Fam Pract 1995;8:221-9.